ArticleBMC cancer2025
Sulforaphane induces cell morphology change and cell apoptosis by activating endoplasmic reticulum stress in glioblastoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unfolded Protein Response in Glioblastoma: Mechanisms of Proteostasis, Tumor Adaptation, and Therapeutic Relevance.Neurochemical research · 2026Review
- Endoplasmic reticulum stress-mediated programmed cell death in the tumor microenvironment.Cell death discovery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSulforaphane (SFN), a naturally occurring isothiocyanate derived from cruciferous vegetables, has shown promise as a multitargeted therapeutic agent in glioblastoma (GBM). This study aimed to elucidate the role and underlying molecular mechanisms of SFN in regulating GBM progression, particularly through the endoplasmic reticulum stress (ERS) and unfolded protein response (UPR) pathways.
methodsPrimary human glioma cells and established GBM cell lines were treated with various concentrations of SFN. RNA sequencing and qPCR analyses were conducted to identify transcriptional changes associated with the UPR pathway. Western blot and immunofluorescence were used to assess the expression and subcellular localization of key ER stress-related proteins. A CHOP knockdown model was employed to examine the functional role of CHOP in SFN-induced apoptosis. Additionally, normal human astrocytes (HA) were used to evaluate the selectivity of SFN's cytotoxicity. In vivo validation was performed using an intracranial glioma xenograft mouse model.
resultsSFN significantly induced apoptotic cell death in GBM cells. Mechanistically, SFN activated multiple branches of the UPR, notably increasing the expression and nuclear translocation of ATF4 and CHOP. CHOP knockdown markedly attenuated SFN-induced apoptosis. RNA-seq and KEGG enrichment analyses confirmed the involvement of the ER stress pathway. Treatment with 4-phenylbutyrate (4-PBA) suppressed SFN-induced cytotoxicity, further supporting ER stress-mediated apoptosis. In vivo, SFN reduced tumor burden and upregulated ER stress markers in intracranial tumor tissues. Importantly, SFN had minimal cytotoxic effects on normal astrocytes, suggesting a favorable therapeutic window.
conclusionsThis study demonstrates that SFN induces GBM cell apoptosis via activation of the UPR pathway, particularly through the ATF4-CHOP axis. These findings support the potential of SFN as a promising therapeutic agent for glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.